SCHEMBL1848472

SCHEMBL1848472

O=C(Nc1cc(Br)nc2ccccc12)C1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
ADORA1 P30542 5/20 0.50
ADORA2A P29274 3/20 0.50
ADORA3 P0DMS8 2/20 0.50
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HPGD P15428 1/20 0.49
CETP P11597 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.47
ATM Q13315 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAOB P27338 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1847991 0.84 IGF1R (0.56) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL1973638 0.83 NPC1 (0.56) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL13646344 0.83 HTT (0.60) NPC1RAB9AADORA1GAASMN1; SMN2
SCHEMBL196744 0.82 MAPT (0.58) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL245791 0.82 SMN1; SMN2 (0.57) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL1845228 0.82 IGF1R (0.56) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL196063 0.81 RXFP1 (0.60) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL196512 0.80 MAPT (0.55) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL196199 0.79 NPC1 (0.52) NPC1RAB9AADORA1ADORA2AADORA3
SCHEMBL934924 0.77 IGF1R (0.52) NPC1RAB9AADORA1ADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323661-B1 A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS UNIV LEIDEN (NL) 2013-04-17 EP disclosed
US-20110144156-A1 A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS UNIVERSITEIT LEIDEN (NL) 2011-06-16 US disclosed
US-20110144156-A1 A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS UNIVERSITEIT LEIDEN (NL) 2011-06-16 US disclosed
EP-2323661-A1 A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS Universiteit Leiden (NL) 2011-05-25 EP disclosed
WO-2010020981-A1 A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS UNIVERSITEIT LEIDEN (NL) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144156-A1 A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS ADORA3, ADORA2A, ADORA1 NPC1 2737/4885RAB9A 1121/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.